Since the formation of Earth approximately 4.5 billion years ago, the convection and release of hot magma in its mantle layer ...

The equipment can be expensive and require hours of labour to fix and maintain. If done correctly, however, laboratory ...

Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

NSAIL director V.S. Subrahmanian unveiled new reports generated by the Northwestern Terror Early Warning System, a ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Research scientist Yosuke Tanigawa and Professor Manolis Kellis at MIT Computer Science and Artificial Intelligence ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in ...

NASA's Europa Clipper mission, featuring SwRI’s MASPEX and UVS instruments, seeks to uncover clues about life-supporting ...

Exact Sciences cuts FY24 revenue view to $2.73B-$2.75B, consensus $2.83B Previous view $2.81B-$2.85B. Cuts FY24 adjusted EBITDA view to $310M-$320M from $335M-$355M.